ProQR Therapeutics (PRQR) Retained Earnings (2013 - 2025)

ProQR Therapeutics (PRQR) has reported Retained Earnings for 13 consecutive years, with -$532.0 million the latest figure, recorded in Q4 2025.

• Quarterly Retained Earnings fell 9.45% year-over-year to -$532.0 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was -$532.0 million (down 9.45% YoY) and the FY2025 annual result came in at -$532.0 million, down 9.45% from the prior year.
• Retained Earnings retreated to -$532.0 million in Q4 2025 per PRQR's latest filing, from -$486.1 million in the prior quarter.
• Over the last five years, Retained Earnings for PRQR reached as high as -$361.6 million in Q4 2021 and fell as low as -$532.0 million in Q4 2025.
• A 5-year average of -$453.5 million and a median of -$456.1 million in 2023 frame the typical range for Retained Earnings.
• Annual changes were most pronounced in 2021 — Retained Earnings decreased 23.29% — and 2023, when it decreased 5.73%.
• Year by year, Retained Earnings stood at -$361.6 million in 2021, then dropped by 19.3% to -$431.4 million in 2022, then slipped by 5.73% to -$456.1 million in 2023, then slipped by 6.56% to -$486.1 million in 2024, then declined by 9.45% to -$532.0 million in 2025.
• According to Business Quant data, Retained Earnings over the past three periods registered -$532.0 million, -$486.1 million, and -$456.1 million for Q4 2025, Q4 2024, and Q4 2023 respectively.